Biggest American-Listed Chinese Pharma -- On April 20, Simcere (SCR) staged a very successful IPO, placing 15.6 million shares at the high end of its range, $14.50. In the open market, Simcere continued to attract attention, rising from the first trade to over $16 before settling back to trade in the mid-$15 dollar range (see our pre-IPO article). While that is something short of an all-time IPO legend, it is very respectable showing and gives Simcere a market value of $1.2 billion, enough to make Simcere the undisputed king of Chinese pharmaceutical companies trading in the US. More details...